Summit Therapeutics plc (SMMT) PT Lowered to $38 at Stifel, But 'Fundamental Conviction Intact'
Stifel analyst Dara Azar lowered the price target on Summit Therapeutics ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)